UK Markets closed

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
163.00-4.87 (-2.90%)
At close: 04:00PM EDT
163.00 0.00 (0.00%)
After hours: 07:59PM EDT
Sign in to post a message.
  • B
    BioPharmaInvestor
    BioNTech's pending exclusive mRNA - LNC Platform deal for oral vaccines with MTNB could help BNTX become a $300 Bil company over the next 5-7 years......Something to ponder going forward.
  • M
    Meili
    COVID-19 Vaccine Demonstrates Strong Immune Response,
    High Efficacy and Favorable Safety in Children 6 Months to
    Under 5 Years of Age Following Third Dose

    https://investors.biontech.de/news-releases/news-release-details/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune
  • J
    Jay
    Pfizer, BioNTech report 80 percent efficacy of Covid-19 vaccine for youngest children
    The companies plan to finish submitting data to the Food and Drug Administration this week. The companies released top-line results showing that three pediatric doses of their Covid-19 vaccine generated a comparable immune response in children as two full doses did in young adults — the primary end goal the FDA set for pediatric vaccine manufacturers. About 19 million children in the U.S. are in this age group, none of whom are currently eligible to receive a Covid-19 vaccine.
  • M
    Midnite
    Why are we down on booster approval when Pfizer is up close to %4?
  • T
    Torsten
    This stock is the perfect choice for the current economic scenario:

    - impending recession: irrelevant
    - China's economic crisis: irrelevant
    - Rising interest rates: irrelevant
    - supply chain issues: none
    - Economic dangers from Russia's invasion: irrelevant
    - energy prices: irrelevant
    - consumer sentiment: irrelevant
  • F
    Faramarz
    The following is the summary from the article in below:

    The immune system involves a host of players, including B cells, which produce antibodies, and T cells, which target infected cells during an infection – and T cells are often part of emerging discussions around vaccine durability.

    A study published in the journal Cell in January showed just how much of a role the other parts of the immune system play in the durability of protection following Covid-19 vaccination.

    The study found that, among 96 vaccinated adults, even though antibody levels decreased against coronavirus variants, the T cells induced by various types of Covid-19 vaccines – the Moderna, Pfizer/BioNTech, Johnson & Johnson and Novavax vaccines – were able to recognize coronavirus variants, including Omicron, even though the vaccines were developed based on the original coronavirus.

    “The important thing for our study was we collected all those samples at the same place with the same techniques and ran all the experiments head-to-head so it was really a fair head-to-head test,” said Shane Crotty, virologist and professor at La Jolla Institute for Immunology, who was an author of the study.

    Plus, those vaccines were developed using different technologies. Moderna and Pfizer/BioNTech are mRNA vaccines. Johnson & Johnson is a viral vector vaccine. Novavax, which is not yet authorized for emergency use in the United States, is a protein-based vaccine.

    “The mRNA vaccines, both Moderna and Pfizer, generated these four categories: antibodies, memory B cells, helper T cells and killer T cells. Overall, the mRNA vaccines generated the best of all four of those,” Crotty said, adding that among people who were vaccinated with Johnson & Johnson, generally there appeared to be less of all four and Novavax appeared to generate somewhat less memory B cells and significantly less killer T cells.

    “So, there were some different mixes there,” Crotty said. “Our immunological data are generally consistent with the vaccine efficacy data that’s out there from the clinical trials and real-world studies that in general, the mRNA vaccines are better than J&J in terms of protection from infection but also protection from hospitalization, with Novavax being somewhere in between, but doing quite well.”

    https://www.cell.com/cell/fulltext/S0092-8674(22)00073-3
  • R
    Rave
    This is going back to $250. By September, it’ll start ramming 300s.
  • D
    DG
    Just to prove how disjointed this market is, on a massive earnings beat a few weeks ago, EPS projected Euro 9 and actual 14, this was up like 2% on that. A year ago, would have rallied 40-70% in a few days... Way undervalued for how much cash on hand, how strong sales continue to be and what the future is for MRNA... Stay the course and look beyond the next few years, great place to be!
  • R
    Ryan
    Performing pretty well on a very red day…
  • T
    Torsten
    Biontech's Share Repurchase Program

    https://investors.biontech.de/de/share-repurchase
  • S
    Sunny Days
    Bought a few more shares today. It’s becoming more and more obvious that covid will be again a big part of our lives this fall/winter.
  • I
    Ira
    “mRNA vaccines superior to others in COVID variant antibody response, study finds”
  • W
    Wim
    The buyback. Note that they call it the first tranche. Note that 40m dollar per week could be the budget for every week till november.
  • B
    Benjo
    Lowest target is 167? I am still for 250+
  • G
    GR8
    Todays Numbers - Catching up

    102,500,000 –- Received Boosters – Since – August 13th (first reported date)
    12.400,000 – Received Second Boosters – One day change – 300,000
    56,976,145 - PFE/BNTX – 52,026 –1 Day change
    43,995,157 – MRNA – 32,464 – 1 Day Change
    1,519,886- J&J – 616 - 1 Day Change
    Retention – % Take Same Booster
    PFE/BNTX - 93.0% (48.01M); otherwise MRNA
    MRNA- 91.8% (35.01M) otherwise PFE/BNTX
    J&J- 23.8% (1.35M); otherwise - 41.1% (2.32M) MRNA - 35.0% (1.98) PFE/BNTX
    258,074,668 Americans - have received 1 dose – 77.7% of US population
    Fully Vaccinated Total
    PFE (2 doses) - 126,855,388
    MRNA (2 doses) - 76,806,824
    J&J (1 dose) - 18,759,463
    Doses Distributed to States (Yesterday) – 783,300
    PFE Delivered – 433,036,335
    MRNA Delivered – 275,224,320
    J&J Delivered- 30,834,800
    First and Second Doses Administered Yesterday –409,031
    Boosters Administered – Yesterday- 78,774
    PFE/BNTX administered including boosters 284,206 (PFE/BNTX) vs 197,525 doses for MRNA-
    One Day Vaccinations (excludes boosters)
    272,702 PFE/BNTX, (of which- 49,873 are second doses)
    186,004 MRNA, (of which – 18,642 are second doses)
    4,151 J&J First Dose –616 (second dose boosters) Market Share Administered-
    Total Administered Excludes Boosters– 582,652,102
    BNTX/PFE –59.03%, MRNA –37.74%%, J&J -3.22%
  • C
    Cal
    On 5/13/22, BNTX repurchased another 273,500 shares at $149.04. Total amount of shares thus far is 588,388.
  • M
    Meili
    FLU
    BNT 161 (Clinical Trial) NCT05052697
    A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY,
    TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE
    AGAINST INFLUENZA IN HEALTHY INDIVIDUALS

    Last Update Posted Date May 20, 2022

    Actual Study Start Date ICMJE September 13, 2021
    Estimated Primary Completion Date January 9, 2023
    (Final data collection date for primary outcome measure)
  • R
    Ryan
    Somebody’s busy purchasing bntx and mrna
  • C
    Cody
    (Updates after panel vote)

    By Manas Mishra and Michael Erman

    May 19 (Reuters) - An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday voted to recommend COVID-19 vaccine booster shots for children ages 5 to 11, at least five months after completing their primary vaccination course.

    The advisers considered data from the CDC that showed protection from two doses starts to wane over time, and that boosters in older age groups improved efficacy against severe COVID and hospitalizations.

    CDC Director Rochelle Walensky still needs to sign off on the committee's recommendation, but signaled at the meeting that she was likely to back the additional shots.

    "We know immunity wanes over time, and we need to do all we can now to protect those most vulnerable," Dr. Walensky said. "It's important for us to anticipate where this pandemic is moving and deploy the tools we have where they will have the greatest impact."

    Just over 29% of U.S. children ages 5-11 are considered fully vaccinated with two doses of the Pfizer/BioNTech shot. The vaccine is not yet authorized for children younger than 5.

    The committee voted 11 to 1 to recommend the additional shots, with one doctor abstaining.

    Dr. Helen Keipp Talbot was the lone committee member to vote against recommending the boosters, arguing that the focus should be on increasing the vaccination rate in the age group.

    "Boosters are great once we've gotten everyone their first round," she said. (Reporting by Manas Mishra in Bengaluru and Michael Erman in New Jersey; Editing by Bill Berkrot)
  • M
    Mashkoor
    6 months to 5 yr BNTX/ PFE vaccine approved by FDA. BNTX can sell directly, without sharing vaccine profit in China, turkey and Germany